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Ferroptosis is a form of nonapoptotic cell death for
which key regulators remain unknown. We sought a
common mediator for the lethality of 12 ferroptosis-
inducing small molecules. We used targeted
metabolomic profiling to discover that depletion of
glutathione causes inactivation of glutathione perox-
idases (GPXs) in response to one class of com-
pounds and a chemoproteomics strategy to discover
that GPX4 is directly inhibited by a second class of
compounds. GPX4 overexpression and knockdown
modulated the lethality of 12 ferroptosis inducers,
but not of 11 compounds with other lethal mecha-
nisms. In addition, two representative ferroptosis in-
ducers prevented tumor growth in xenograft mouse
tumor models. Sensitivity profiling in 177 cancer
cell lines revealed that diffuse largeB cell lymphomas
and renal cell carcinomas are particularly susceptible
to GPX4-regulated ferroptosis. Thus, GPX4 is an
essential regulator of ferroptotic cancer cell death.INTRODUCTION
Cells can undergo regulated forms of cell death in a variety of
contexts (Galluzzi et al., 2012), including during development
(Penaloza et al., 2006). Activation of alternative regulated cell
death mechanisms may be beneficial for treating diseases
such as cancer, in which apoptotic cell death mechanisms are
suppressed due to genetic alterations. Indeed, activation of
alternative cell death pathways may overcome the drug resis-
tance associated with existing chemotherapeutic agents,
providing new drug targets.Regulators of apoptosis have been targeted with small mole-
cules to induce cell death in cancer cells (Cotter, 2009). Recently,
regulated, nonapoptotic cell death processes have been discov-
ered, including necroptosis (Degterev et al., 2005) and ferropto-
sis (Dixon et al., 2012).
Ferroptosis is a mode of cell death involving the production of
iron-dependent reactive oxygen species (ROS). In engineered
human fibroblast cell lines, the small molecule erastin was found
to induce preferential lethality in cells overexpressing oncogenic
HRAS (Dolma et al., 2003). Erastin-induced ferroptotic cell death
was distinct from apoptosis, necrosis, and autophagy, based on
morphological, biochemical, and genetic criteria. Ferroptosis
involves metabolic dysfunction that results in the production of
both cytosolic and lipid ROS, independent of mitochondria but
dependent on NADPH oxidases in some cell contexts (Dixon
et al., 2012).
We have reported the identification of additional small mole-
cules, named RSL3 (Yang and Stockwell, 2008a), ML162, and
DPI10 (Weı¨wer et al., 2012), that display oncogenic-RAS-
synthetic-lethality (the RSL phenotype) in engineered fibro-
blast-derived tumorigenic cell lines. Here, we sought to test
whether these and other compounds also induce ferroptosis,
and whether they could be used to elucidate a central regulator
of ferroptosis, which controls cell death by all FIN (ferroptosis
inducing) compounds.
We focused initially on erastin and RSL3. Erastin reprograms
cancer cell metabolism by modulating VDAC2/VDAC3 (Yagoda
et al., 2007) and system xc
 (Dixon et al., 2012) to trigger ferrop-
tosis, whereas RSL3-induced ferroptosis is not dependent on
these factors (Yang and Stockwell, 2008a) but results in a similar
downstream cell death phenotype. Thus, we viewed erastin and
RSL3 as ideal probes to elucidate conserved downstream regu-
lators of ferroptosis. We used metabolomic profiling to evaluate
comprehensively changes in metabolism occurring upon erastin
treatment, and chemoproteomics to identify candidate targetCell 156, 317–331, January 16, 2014 ª2014 Elsevier Inc. 317
proteins for RSL3, which led to the discovery of a common
pathway regulating cell death in response to all known com-
pounds that induce ferroptosis.
RESULTS
Erastin Depletes Glutathione to Trigger Selective
Ferroptosis
To investigate the global changes in metabolism induced by era-
stin, we treated HT-1080 fibrosarcoma cells with DMSO or era-
stin, and extracted polar and lipid metabolites. The metabolite
extract was subjected to liquid chromatography-tandem mass
spectrometry (LC-MS/MS) analysis to determine the quantity
149 polar and 115 lipid metabolites (Table S1 available online;
Figure 1A). Both reduced glutathione (GSH) and oxidized gluta-
thione (GSSG) were depleted significantly upon erastin treat-
ment, whereas the level of lysophosphatidyl cholines (lysoPCs)
was increased; the increase in lysoPCs may reflect the genera-
tion of lipid ROS during erastin-induced ferroptosis because
PCs have been found to be converted to lysoPCs (deacylated
PCs) upon lipid oxidation (Parthasarathy et al., 1985).
The significant depletion of GSH/GSSG was consistent with
the fact that erastin induces the formation of ROS, causing an
oxidative cell death. GSH/GSSGconstitutes amajor cellular anti-
oxidant system and provides reducing equivalents to eliminate
oxidative species. We treated three cell lines with erastin, deter-
mined GSH levels using Ellman’s reagent, and confirmed the
dose-dependent, GSH-depleting effect of erastin (Figures 1B
and S1A). We found that GSH depletion by erastin is necessary
for erastin’s lethality because supplementing the culturemedium
with GSH or N-acetylcysteine (NAC), a biosynthetic precursor to
GSH, prevented erastin-induced cell death (Figure S1B).
We sought to test further whether the glutathione-depleting
activity of erastin was essential for lethality. We established a
synthetic route to create six erastin analogs (see Data S1 for
synthesis) and tested these analogs for selective lethality in
BJ-derived engineered cell lines (Figure 1C). Three compounds
(MEII, PE, and AE) retained selective lethality, whereas three
compounds (A8, PYR, and dMK) were not lethal (Figure 1C).
Lethal analogs of erastin depleted cellular GSH more effectively
than nonlethal analogs of erastin (Figure 1D), which further sug-
gested that the GSH-depleting activity of erastin is necessary for
erastin lethality.
We reasoned that, if GSH depletion was contributing to
erastin’s lethality, then GSH depletion by other reagents might
partially mimic erastin’s selective lethality in the BJ-cell line sys-
tem, which consists of isogenic cell lines (two with and two
without oncogenic HRAS), through which ferroptosis-inducing
compounds such as erastin were discovered. When the four
BJ-derived cells were treated with BSO, an oncogenic HRAS-
selective lethal phenotype was observed under conditions of
low cell density (Figure 1E), suggesting that GSHdepletion is suf-
ficient for induction of ferroptosis in BJ cells with oncogenic
HRAS overexpression, although additional factors may enhance
the potency and efficacy of the lethality caused by GSH deple-
tion under more general circumstances. These results indicated
that erastin depletes GSH through preventing cystine uptake via
inhibition of system xc
 (Dixon et al., 2012).318 Cell 156, 317–331, January 16, 2014 ª2014 Elsevier Inc.Erastin Inactivates GPX Enzymes through GSH
Depletion
Given that we found GSH depletion to be critical for erastin-
induced ferroptosis, we investigated how GSH depletion by era-
stin was able to induce selective lethality in the engineered BJ
cell lines. It has been hypothesized that most cancer cells,
including RAS-transformed fibroblasts (Irani et al., 1997), are
under high levels of oxidative stress (Szatrowski and Nathan,
1991), which therefore needs to be counteracted by increasing
the ROS-scavenging capacity, to prevent oxidative damage
(Hussain et al., 2003). In this model, targeting ROS-scavenging
systems through multiple points, including GSH depletion,
would cause an imbalance in this equilibrium, leading to oxida-
tive cell death (Trachootham et al., 2006). In order to test
whether this simple hypothesis could explain erastin’s selective
lethality, we examined basal ROS levels in the BJ-derived engi-
neered cell lines using H2DCF, a cytosolic ROS sensor, and
confirmed that BJeLR cells have modestly elevated ROS levels
compared to BJeH (BJ-TERT) and BJeHLT (BJ-TERT/LT/ST)
cells (Figure 2A). We then treated the four BJ-derived cell lines
with an SOD inhibitor (DETC), a thiol-reactive reagent (DIA), a
thioredoxin reductase inhibitor (DCNB), or a catalase inhibitor
(ATZ) (Figures 2B and S2). Three of these antioxidant inhibitors
(DETC, DIA, and DCNB) killed BJ-derived cells, but they neither
depleted GSH nor displayed selective lethality, which was in
contrast to the two GSH-depleting reagents, erastin and BSO
(Figures 2B, 2C, and S2). The results indicate that it is not
possible to induce selective ferroptosis in the BJ-derived cell
lines by simply targeting the antioxidant network. Instead,
unique biochemical and metabolic changes downstream of
GSH depletion were likely to be responsible for the selective
induction of ferroptosis.
The degree of GSHdepletion upon erastin treatment in the four
BJ cell lines was also examined (Figure 2D). We found that these
four BJ-derived cell lines contained varying amounts of basal
GSH in the absence of any treatment, as reported previously
by Kang and Enger (1992), but were depleted of GSH to a similar
extent upon erastin treatment. The concentration of erastin used
in this experiment (10 mM) was lethal to BJeLR and DRD cells
(expressing HRASV12) but was not lethal to BJeH and BJeHLT
cells (with wild-type RAS), even upon prolonged incubation (Fig-
ure 2B). Therefore, the selective lethality among these cell lines
was not caused by differential depletion of GSH or by differences
in the basal level of GSH.
We then treated BJeLR cells with either GSH-depleting
reagents (erastin or BSO) or other antioxidant-targeting re-
agents (DETC, DIA, and DCNB), and stained cells with either
BODIPY-C11, a membrane-targeted lipid ROS sensor, or
H2DCF, a cytoplasmic ROS sensor, to detect changes in
ROS accumulation upon compound treatment (Figure 2E).
GSH-depleting reagents strongly increased BODIPY-C11 and
H2DCF signals, whereas other antioxidant inhibitors did not
increase the fluorescence signals from either ROS sensor, indi-
cating that both cytosolic and lipid ROS levels were increased
selectively by GSH depletion in the oncogenic HRAS-containing
cell lines (Figure 2E).
We considered that one consequence of GSH depletion could
be inactivation of glutathione-dependent peroxidases (GPXs).
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Figure 1. Ferroptosis Involves Generation of Lyso-PC and Depletion of Glutathione
(A) Changes in metabolites upon erastin treatment.
(B) Dose-dependent depletion of GSH by erastin in HT-1080 cells and U-2 OS cells.
(C) Structure and activity of erastin (ERA) analogs. Potency (GI50; concentration required for 50% growth inhibition) and selectivity (ratio of GI50 in HRASwild-type
cells divided by GI50 in HRAS mutant cells) of each analog are shown. PYR, pyridine erastin; AE, aldehyde erastin; MEII, morpholine erastin II; PE, piperazine
erastin.
(D) GSH depletion by erastin analogs. HT-1080 cells were incubated with 10 mM erastin analogs for 5 hr or 100 mM BSO for 12 hr. BSO was used as a positive
control for GSH depletion. Data were normalized to the DMSO sample. Box-and-whisker plots (n = 3–8) are as follows: midline representsmedian, box is the 25th–
75th percentiles, and whiskers are minimum and maximum. ***p < 0.001.
(E) BSO induces selective lethality in BJ-derived tumorigenic cells expressing oncogenic HRAS. Scale bars, 60 mm.
In (B) and (E), data are presented as mean ± SD (n = 3). See also Figure S1 and Table S1.
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Figure 2. GSH Depletion Inactivates GPX
Enzymes to Induce Ferroptosis
(A) Basal ROS levels among BJ-derived cell lines
were compared (n = 8).
(B) The growth inhibition effect of antioxidant-
targeting compounds was determined in the
four BJ-derived cells (n = 3). The bar graph in-
dicates growth inhibition at two different concen-
trations (23 GI50 and 43 GI50 for each compound
in BJeLR cells).
(C) Other antioxidant inhibitors do not deplete GSH
during cell death (n = 3).
(D) Erastin depletes cellular GSH equally in the four
BJ-derived cell lines.
(E) GSH-depleting reagents elevated both cyto-
solic and lipid ROS level, whereas other antioxidant
inhibitors did not (n = 3).
(F) GSH-depleting reagents (ERA and BSO) in-
hibited GPX activity. Rel. Abs., relative absor-
bance.
n.s., not significant; *p < 0.05; ***p < 0.001. Error
bars in (B), (C), and (E) represent mean ± SD. See
also Figure S2.GPXs catalyze the reduction of hydrogen peroxide and organic
hydroperoxides to water or the corresponding alcohols, using
GSH as an essential cofactor (Brigelius-Flohe´ and Maiorino,
2013).
The total activity of GPXs in BJeLR cells was examined using
tert-butylhydroperoxide (tBuOOH) as a substrate, by monitoring
the rate of NADPH oxidation, which is coupled to the tBuOOH-
reducing activity of GPXs in cell lysates.When BJeLR cell lysates
treated with vehicle only (0.08% DMSO) were added to the GPX
activity assay, we observed a decrease in the amount of NADPH,
indicating that tBuOOH was reduced by GPXs in the cell lysate
(Figure 2F). Treatment of BJeLR cells with antioxidant inhibitors
(DETC, DIA, and DCNB) did not affect GPX activity because the
rate of NADPH oxidation was similar to the vehicle-only-treated
sample.
When lysates from BJeLR cells that had been treated with
GSH-depleting reagents (erastin or BSO) were analyzed, NADPH
oxidation was prevented, indicating that GPXs were inactivated
upon GSH depletion (Figure 2F). Taken together, these data indi-
cate that erastin and BSO inactivate cellular GPXs, leading to the
generation of cytoplasmic and lipid ROS. Other antioxidant in-
hibitors did not deplete GSH, an essential cofactor for GPX
enzyme activity, and therefore, did not inhibit GPX activity and
did not cause accumulation of peroxides.320 Cell 156, 317–331, January 16, 2014 ª2014 Elsevier Inc.RSL3Binds to and Inactivates GPX4
Having determined that erastin acts
by depleting GSH and inhibiting GPXs,
we examined the mechanism of action
of RSL3, another ferroptosis inducer
(Yang and Stockwell, 2008a). Cell death
induced by erastin and RSL3 shared
common ferroptotic features, such
as iron, MEK, and ROS dependence;
however, RSL3 was not dependent on
VDAC2/VDAC3 or system xc
 implyingthat a different initiating mechanism could converge on a similar
form of ferroptotic cell death. We thus used RSL3 as a probe to
illuminate the shared downstream mechanism involved in
executing ferroptosis.
When we examined cellular GSH levels during RSL3-induced
cell death, we found that GSH remained unaffected by a
lethal RSL3 concentration (2 mM) in BJeLR cells, which was in
contrast to erastin’s effect (Figure 3A). However, BODIPY-C11
staining revealed the generation of lipid ROS in RSL3-treated
BJeLR cells, which indicated that lipid oxidation is common to
both erastin-induced and RSL3-induced ferroptotic cell death
(Figure 3B).
In order to understand the mechanistic basis of RSL3’s enig-
matic induction of lipid ROS in the absence of GSH depletion,
we used affinity-based chemoproteomics to identify candidate
target proteins for RSL3. We discovered that the chloroaceta-
mide moiety of RSL3 was essential for its activity and that
replacement with other electrophiles resulted in a loss of potency
(Table S2; see Data S1 for synthesis). These data suggested that
RSL3 targets an enzyme with a nucleophilic active site, such
as serine, threonine, cysteine, or selenocysteine. Despite the
potential for promiscuous reactivity of the chloroacetamide, we
discovered that only the (1S, 3R)-RSL3 diastereomer of RSL3 ex-
hibited selective lethality in the BJ cell system, whereas the three
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Figure 3. RSL3 Binds to and Inhibits GPX4
(A) RSL3 does not deplete GSH. The level of GSH was determined after treating with 2 mM RSL3, 10 mM erastin, or 1 mM BSO (n = 3; *p < 0.05). Error bars
indicate ± SD.
(B) RSL3 treatment increased lipid ROS level, as erastin did.
(C) The structure of (1S, 3R)-RSL3 is shown.
(D) Only the (1S, 3R) diastereomer displayed selective lethality in HRASV12-expressing cells in the four BJ-derived cell lines.
(E) Structure of RSL3 affinity probes used in the chemoproteomics experiments is shown. Fcn, fluorescein affinity tag.
(F) The active affinity probe with the (1S, 3R) stereochemistry exhibited selective lethality against cells with HRASV12, whereas an affinity probe with the (1R, 3R)
stereochemistry was not lethal.
(legend continued on next page)
Cell 156, 317–331, January 16, 2014 ª2014 Elsevier Inc. 321
other diastereomers of RSL3 lacked selectivity and were more
than 100-fold less potent (Figures 3C and 3D; Table S2; Data
S1 for synthesis). These results suggested that (1S, 3R)-RSL3
covalently binds to one or more proteins to induce the potent
and selective lethality observed in BJ cells expressing HRASV12.
Affinity reagents were synthesized by attaching an isobutyryl-
protected fluorescein tag via a polyethylene glycol (PEG) linker
to the phenyl substituent at the 1 position in the tetrahydro-
b-carboline ring system of RSL3, which was found to tolerate
structural modifications. Despite a loss in potency upon incorpo-
ration of the affinity tag, 10-fold oncogenic HRAS selectivity was
retained for an affinity analog with the active (1S, 3R) stereo-
chemistry, whereas an affinity analog with the (1R, 3R) stereo-
chemistry showed no activity (Figures 3E and 3F; see Data S1
for synthesis).
Samples for proteomic analysis were prepared by treating
intact BJeLR cells with (1S, 3R)-RSL3-fluorescein (active probe
treatment), (1R, 3R)-RSL3-fluorescein (inactive probe treat-
ment), or (1S, 3R)-RSL3-fluorescein pretreated with free (1S,
3R)-RSL3 (competitor treatment). Treated cells were lysed, and
fluorescein-tagged proteins were affinity purified using Sephar-
ose beads coupled to an anti-fluorescein antibody. Eluted
proteins were identified with a Synapt G2 HDMS mass spec-
trometer (Waters) using a quantitative label-free shotgun proteo-
mic strategy with data-independent scanning (MSE) and ion
mobility spectrometry (see Extended Experimental Procedures).
Proteins enriched in ‘‘active probe’’ versus ‘‘inactive probe’’
and ‘‘active probe’’ versus ‘‘competitor’’ treatments were deter-
mined (Figure 3G). Three independent affinity preparations of
each of these treatments were further subsampled in three LC-
MS/MS analyses (Table S2). Candidates were chosen on the
basis of (1) exhibiting enrichment in both active:inactive and
active:competitor comparisons with p < 0.01 (with false discov-
ery rate correction; see Extended Experimental Procedures) and
(2) identification and quantitation by n > 2 tryptic peptides. This
analysis ranked GPX4 (glutathione peroxidase 4, PhGPx) as
the top candidate protein target for (1S, 3R)-RSL3 (Figure 3G;
Table S2).
It was intriguing that GPX4 was identified as the most highly
ranked candidate in our unbiased chemoproteomic approach
to find target proteins for RSL3 because erastin inhibited cellular
GPX enzymes through GSH depletion (Figures 1 and 2). We
confirmed that GPX4 was purified specifically by the affinity
analog (1S, 3R)-RSL3-fluorescein, using fresh samples prepared
from BJeLR cells treated with the active probe, the inactive
probe, or the competitor as before, analyzed for GPX4 abun-
dance by western blot (Figures 3H and S3A).
In order to examine whether RSL3 binding to GPX4 inactivates
the peroxidase activity of GPX4, we treated a clone of the COH-(G) Affinity-based chemoproteomics identified GPX4 (red dot) as the most likely
indicated condition and their FDR-adjusted p values were represented as volcan
(H) Confirmation of GPX4 binding to active (1S, 3R)-RSL3 affinity probe. Left pane
as rendered by TransOmics software. Right panel: cell lysates prepared from BJe
presence of competitor (A+C) that were affinity purified by a-fluorescein antibod
using GPX4-specific antibody.
(I) (1S, 3R)-RSL3 inhibits enzyme activity of GPX4.
See also Figure S3 and Table S2.
322 Cell 156, 317–331, January 16, 2014 ª2014 Elsevier Inc.BR1 breast cancer cell line overexpressing GPX4 (L7G4), with
(1S, 3R)-RSL3 or vehicle only, prepared cell lysates, and incu-
bated them with 7a-cholesterol hydroperoxide (7a-cholesterol-
OOH) to determine the rate of reduction to the corresponding
alcohol (7a-cholesterol-OH). 7a-cholesterol-OOH is a specific
substrate for GPX4; no other GPX enzyme can catalyze the
reduction of 7a-cholesterol-OOH (Kriska and Girotti, 2005). In
vehicle-treated samples, 7a-cholesterol-OOH decreased over
time in a GSH-dependent manner, due to reduction by GPX4
in the lysate. Upon treatment with (1S, 3R)-RSL3, however, no
reduction of 7a-cholesterol-OOH was observed, indicating that
GPX4 was inhibited by (1S, 3R)-RSL3 (Figure 3I; see Figure S3B
for quantitation data). Treatment with the inactive diastereomer
(1R, 3R)-RSL3 did not inhibit GPX4 activity (Figure S3C).
We used another proteomics data analysis tool, Elucidator
(Rosetta Biosoftware), and found that only GPX4 was a signifi-
cantly enriched protein common to both TransOmics and
Elucidator analysis algorithms (Figure S3D). Evaluation of other
candidates using specific siRNAs and shRNAs failed to show
either modulation of (1S, 3R)-RSL3 sensitivity or cell killing (Fig-
ures S3E–S3I), which excludes the functional role of these other
binding proteins on ferroptosis induced by (1S, 3R)-RSL3.
RNAi-Mediated GPX4 Knockdown Induces Ferroptosis
We hypothesized that, if RSL3 were to inhibit a protein essential
for cancer cell viability, then reducing the levels of this protein
would sensitize cells to RSL3. Silencing of GPX4 mRNA using
shRNAs that cause partial knockdown of GPX4 strongly sensi-
tized cells to (1S, 3R)-RSL3 (Figure 4A). Conversely, when we
overexpressed GPX4, we found that it caused strong resistance
to (1S, 3R)-RSL3 lethality (Figure 4B), as expected for a relevant
target protein.
We were able to achieve a more effective knockdown of GPX4
using a pool of siRNAs targeting GPX4 (20-fold decrease in the
GPX4 mRNA; Figure S4A) compared to a single clone of shRNA
(5-fold decrease in the GPX4 mRNA; Figure 4A). With this more
effective knockdown, HT-1080 cells underwent cell death with
accompanying lipid ROS generation (Figure 4C). Cell death
induced by siGPX4 was rescued by the same suppressors of
RSL3—an iron chelator (DFOM), a MEK inhibitor (U0126), and
an antioxidant (vitamin E [Vit. E])—which suggested that GPX4
knockdown induced ferroptotic cell death (Figure 4D) similar to
RSL3. None of these ferroptosis inhibitors suppressed cell death
induced by siDeath, a control siRNA pool targeting multiple
essential genes, highlighting the ferroptosis-specific action of
these inhibitors (Figure 4D). Furthermore, siGPX4 induced selec-
tive cell death in BJeLR and DRD cells (with HRASV12), but not
BJeH and BJeHLT cells (wild-type HRAS), which recapitulated
the selective lethality of erastin and RSL3 (Figures 4E andbinding protein for (1S, 3R)-RSL3. Fold enrichment values of peptides at the
o plots. The top three candidates are shown.
l is a 3D visualization of isotopic clusters of peptide ILAFPCNQFGK from GPX4
LR cells treated with active probe (A), inactive probe (I), or active probe in the
ies. Then, the purified protein samples were probed for GPX4 by western blot
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Figure 4. RSL3 Targets GPX4 to Induce Ferroptosis
(A) Knockdown of GPX4 using shRNAs rendered HT-1080 cells hypersensitive to (1S, 3R)-RSL3 lethality.
(B) Overexpression of GPX4 rendered HT-1080 cells resistant to (1S, 3R)-RSL3 lethality.
(C) HT-1080 cells transfected with a pool of siRNAs targeting GPX4 showed increased lipid ROS level as assessed by BODIPY-C11 staining. siNeg has no
homology to any known mammalian genes and was used as a negative control.
(legend continued on next page)
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S4B). These data suggested that GPX4 is the primary target of
RSL3, mediating its ability to induce ferroptosis specifically in
the oncogenic HRAS-containing BJ-derived fibroblasts.
There are eight isoforms of GPXs in humans with different tis-
sue expression and substrate specificities. In BJeLR cells, six
GPX isoforms are expressed (GPX1, GPX2, GPX3, GPX4,
GPX7, and GPX8) as determined by RT-qPCR (Figure S4C).
Knockdown of each isoform affected cell viability to varying
levels; however, GPX4 knockdown was the most lethal to BJeLR
cells, which highlights the prominent role of GPX4 inhibition in
inducing cell death, as compared to other GPX enzymes (Figures
4F and S4D).
Taken together, these data suggest that GPX4 is a central
regulator of ferroptosis induced by erastin and RSL3. Cell death
was enhanced in the BJ-derived cell lines expressing HRASV12
due to the increased basal ROS (Figure 2A) and enhanced lipid
peroxidation after GPX4 inhibition, which caused selective
lethality in this engineered isogenic cell line model.
GPX4 Regulates Ferroptosis Induced by 12 Divergent
Compounds
In a larger screening campaign to find additional FIN com-
pounds, 14 candidate compounds were discovered out of
more than a million tested (Figure 5A; see Figure S5 for struc-
tures) (Weı¨wer et al., 2012; Yang et al., 2012). These 14 com-
pounds displayed selective lethality in HRASV12-expressing cells
in the four BJ-derived cell lines (Figure 5A; Table S3). We defined
ten structurally diverse FIN groups, not including erastin or RSL3
(Figure 5A), to use in subsequent experiments.
BJeLR cells treated with each of the ten additional FIN com-
pounds exhibited an increase in BODIPY-C11 fluorescence,
indicating that lipid ROS were generated (Table S3 for individual
flow cytometry data). We then tested 11 non-FIN compounds
acting through diverse lethal mechanisms to see whether they
induced lipid ROS generation using this assay (Table S3 for
more information of 11 non-FIN compounds). These 11 diverse
lethal compounds were confirmed to lack selective lethality in
the four BJ-derived cell lines previously (Root et al., 2003), which
suggested that they are not ferroptosis inducers. We found that
10 out of 11 of the non-FIN compounds did not generate lipid
ROS, implying a specificity of lipid ROS generation for FIN
compound-treated cells (Table S3 for individual flow cytometry
data). It is likely that the reported ROS-generating activity of
phenylarsine oxide was responsible for the oxidation of the
BODIPY-C11 dye (Fane´lus and Desrosiers, 2008).
In order to determinewhether these FIN compounds genuinely
induced ferroptosis, the functional requirement of lipid ROS dur-
ing ferroptosis was examined by treating BJeLR cells with each
lethal compound (FINs and non-FINs) in the presence of a lipo-
philic antioxidant, butylated hydroxytoluene (BHT). BHT strongly(D) Known inhibitors of ferroptosis, 10 mM U0126, 100 mM Vit. E, or 100 mM DFO
suppress cell death induced by siDeath.
(E) Knockdown of GPX4 displayed selective lethality in the four BJ-derived isoge
(F) Other GPX isoforms are not relevant to ferroptotic cell death.
The values in (D)–(F) were normalized to control samples transfected with siNeg.
Data in (A) and (B) are presented as mean ± SD (n = 3).
See also Figure S4.
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for individual growth inhibition curves). The rescuing effect of
BHT was specific to FIN compounds because BHT was not
able to suppress cell death induced by 12 non-FIN compounds
(Table S3 for individual growth inhibition curves). We quantified
the degree of cell death suppression by calculating the normal-
ized differences in the AUC (area under the concentration-
response curve) of the compound alone and that of the
compound with BHT. Combined with the BODIPY-C11 staining
data, these results revealed that the FIN compounds are mech-
anistically distinct from the 11 non-FIN compounds (Figure 5B).
An extended death mechanism analysis using the modulatory
profiling approach (Wolpaw et al., 2011) with four selected FIN
compounds (erastin, PE, DPI2, and DPI10) revealed that they
induced a similar form of cell death that was distinct from non-
FIN compounds (Figure 5C). Taken together, these data indicate
that compounds that display the RSL phenotype in the four-BJ
cell system are ferroptosis inducers. These data also suggest
that ferroptotic cell death is not limited to erastin and RSL3
but that a number of additional small molecules can be identified
that induce ferroptosis, suggesting that it may be a more gener-
ally important mechanism of lethality.
In order to determine the generality of ferroptosis regulation by
GPX4, we treated HT-1080 cells with each lethal compound (FIN
compound or non-FIN compound) under a GPX4-inhibited con-
dition (using BSO treatment, which depletes glutathione and
therefore inhibits all GPXs), or a GPX4-upregulated condition
(by overexpressing GPX4). GPX4 inhibition using BSO enhanced
ferroptotic cell death induced by all FIN compounds, whereas
GPX4 overexpression suppressed ferroptosis induced by all
FIN compounds (Figure 5D and Table S3). The modulation effect
of BSO and GPX4 overexpression was specific to FIN com-
pounds because their effects on cell death induced by 11 non-
FIN compounds were minimal (Figure 5D).
We speculated that these additional FIN compounds acted
through mechanisms similar to those induced by erastin or
RSL3; we examined whether these FIN compounds inhibited
GPX4 in BJeLR cells. For a side-by-side comparison of GPX4
activity in multiple samples, we used an LC-MS-based GPX4
assay in which the GPX4 enzyme activity in cell lysates was
measured by their capacity to reduce exogenously added
phosphatidylcholine hydroperoxide (PC-OOH), a GPX4-specific
substrate. When GPX4 was inhibited, cells could not reduce PC-
OOH, which resulted in a signal for the [PC-OOH + H]+ ion (m/z,
790.6) in the mass chromatogram. BJeLR cells treated with any
of the eight FIN compounds (DPI7, DPI10, DPI12, DPI13, DPI17,
DPI18, DPI19, and RSL3) lacked GPX4 activity, being unable to
reduce exogenous PC-OOH (Figure 5E). On the other hand, a
control non-FIN compound, staurosporine, and two known FIN
compounds, erastin and DPI2, did not inhibit GPX4 activity inM, were able to suppress siGPX4-induced cell death, whereas they could not
nic cell lines.
Bar graphs in (C)–(F) are mean ± SD (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001.
A B
C
E
D
F G
(legend on next page)
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the assay. The LC-MS-based assay requires addition of exoge-
nous GSH (5 mM) in the reaction mixture; therefore, it cannot
detect indirect inhibitory effects on GPX4 by GSH-depleting
agents such as BSO and erastin.We then determined the cellular
GSH level in BJeLR cells treated with DPI2, the one FIN com-
pound that did not inhibit GPX4 in the LC-MS-based assay,
along with BSO and erastin as positive controls, and staurospor-
ine as a negative control (Figure 5F). DPI2 depleted 90% of
cellular GSH compared to untreated BJeLR cells, indicating
that it acts through a mechanism similar to erastin to induce
ferroptotic cell death (Figure 5F).
These results demonstrate that GPX4-regulated ferroptosis is
a common mechanism shared by multiple independent small
molecule scaffolds. All FIN compounds can be categorized
into two classes based on the mode of GPX4 inhibition. One
class, including erastin, inhibits GPX4 through GSH depletion.
The second class inhibits GPX4 without GSH depletion, such
as RSL3, which inhibits GPX4 directly (Figure 5G).
Ferroptosis Inducers Inhibit Tumor Growth in a
Xenograft Mouse Model
We explored whether the GPX4-regulated ferroptotic cell death
pathway could be utilized to suppress the growth of tumors in
a xenograft mouse model. First, we searched for a pharmacody-
namic marker associated with ferroptotic cell death. A set of 83
genes that were known to be perturbed upon oxidative stress
was surveyed to determine whether the expression level of any
gene was affected during ferroptosis induced by erastin or
RSL3 (Figure 6A; Table S4). This analysis revealed that PTGS2,
a gene encoding cyclooxygenase-2 (COX-2), was the most
upregulated gene in BJeLR cells upon treatment with either era-
stin or (1S, 3R)-RSL3 (Figure 6A). The functional relevance of
PTGS2 on ferroptosis was examined using indomethacin, a
PTGS-1/PTGS-2 (COX-1/COX-2) inhibitor. Ferroptotic cell death
by erastin or (1S, 3R)-RSL3 was not affected by indomethacin
treatment, suggesting that PTGS2 upregulation is simply a
downstream marker of ferroptosis (Figure S6A).
We also developed a more effective analog of erastin that
could be tested in vivo. Erastin itself has modest water solubility
and is metabolically labile, precluding its use in vivo. We discov-
ered that introduction of a piperazine moiety into the aniline ring
of erastin resulted in a more water-soluble and more metaboli-
cally stable compound that was suitable for in vivo experiments;Figure 5. Ferroptosis Occurs through a GPX4-Regulated Pathway
(A) Discovery of additional FINs based on selective lethality in the four BJ cell lin
(B) FINs (red) are distinct from non-FINs (blue) in accompanying lipid ROS
antioxidant, BHT.
(C) Modulatory profiling (Wolpaw et al., 2011) with erastin, PE, DPI2, DPI10, and ot
of cell death as erastin in HT-1080 cells. DAUC with a positive sign indicates sup
death modulators upon lethal compound treatment.
(D) Inhibition of GPX4 by BSO sensitized cells to death induced by 12 FIN compo
the lethality of FIN compounds.
(E) Eight structurally diverse FIN compounds inhibited GPX4, whereas two FIN com
FIN compound, did not show direct GPX4 inhibition in this LC-MS-based assay.
(F) The two FIN compounds, DPI2 and erastin, depleted cellular GSH, which inh
indicates mean ± SD (n = 3).
(G) Model of GPX4-regulated ferroptosis pathway. Ferroptosis inducers can be c
*p < 0.05; ***p < 0.001. See also Figure S5 and Table S3.
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lated PTGS2 in BJeLR cells (Figure 6B). Cotreatment of Vit.
E suppressed PTGS2 induction by PE, which indicates that
PTGS2 upregulation is downstream of the lipid peroxidation
that occurs during ferroptosis (Figure 6B). (1S, 3R)-RSL3, but
not (1R, 3R)-RSL3, increased PTGS2 expression (Figure 6B). In
addition, knockdown of GPX4 using siRNAs markedly increased
PTGS2mRNA abundance, whereas the effect on PTGS2mRNA
abundance of siDeath was minimal (Figure 6B). Kumagai et al.
(2004) reported upregulation of PTGS2 by 4-HNE, an end
product of oxidized lipids in an atherosclerosis model. Moreover,
DNA microarray analysis of gene expression in skin tissue sam-
ples obtained fromGpx4-deficient mice identified Ptgs2 as a key
gene upregulated as a consequence of Gpx4 loss (Sengupta
et al., 2013). Taken together, these data confirm that PTGS2
upregulation is a suitable marker for the lipid peroxidation that
occurs during GPX4-regulated ferroptosis.
We tested whether (1S, 3R)-RSL3 could prevent tumor growth
in athymic nude mice implanted with subcutaneous (s.c.) xeno-
graft tumors derived from BJeLR cells. Mice were injected with
BJeLR cells s.c. and then with 100 mg/kg (1S, 3R)-RSL3 in the
same site 1 day later. The (1S, 3R)-RSL3 injection was repeated
twice each week for 2 weeks. Three weeks later, we observed
significant prevention of tumor growth in (1S, 3R)-RSL3-treated
animals (Figure 6C; p = 0.0053). Subsequently, we examined
the ability of (1S, 3R)-RSL3 to shrink preexisting tumors in a ther-
apeutic study, using s.c. xenograft tumors that had been allowed
to grow for 1 week and then treated with 100 mg/kg (1S, 3R)-
RSL3 twice a week for 2 weeks. Again, we observed a significant
reduction in tumor volume compared with the vehicle-treated
control group, with this infrequent dosing (Figure 6C; p =
0.038). The inhibition of tumor growth was likely due to the induc-
tion of ferroptosis, as determined by Ptgs2 upregulation in
(1S, 3R)-RSL3-treated tumors (Figure 6C).
We then evaluated the erastin analog PE in a tumor-prevention
model using nude mice into which HT-1080 cells, the human
fibrosarcoma cell line, had been injected. As mentioned, PE
has improved metabolic stability (Figure 6D) and water solubility
(0.086mM for erastin versus 1.4mM for PE) compared to erastin.
PE was affected similarly by cell deathmodulators as erastin and
displayed a distinct pattern from other non-FIN lethal com-
pounds, indicating that PE, like erastin, induces ferroptosis in
HT-1080 cells (Figure 5C; Spearman correlation coefficient,es.
generation during the cell death process and in death suppression by an
her lethal molecules confirmed that PE, DPI2, and DPI10 induced a similar form
pression of cell death, whereas a negative sign indicates sensitization by cell
unds, whereas activation of GPX4 by cDNA overexpression rescued cells from
pounds, DPI2 and erastin, and the negative control staurosporine (STS), a non-
ibits GPX4 indirectly, whereas staurosporine did not deplete GSH. Bar graph
ategorized into two classes based on the mode of GPX4 inhibition.
AD
B
C
E
Figure 6. Ferroptosis Suppresses Tumor Growth in a Xenograft Mouse Model
(A) Upregulation of PTGS2 expression upon erastin and (1S, 3R)-RSL3 treatments.
(B) PTGS2 expression was induced by PE, (1S, 3R)-RSL3, and siGPX4, but not by PE with Vit. E, (1R, 3R)-RSL3, and siDeath.
(C) (1S, 3R)-RSL3 inhibited tumor formation and tumor progression through induction of ferroptosis as demonstrated by upregulation of PTGS2 in the tumors.
(1S, 3R)-RSL3 was administered s.c. twice a week for 2 weeks.
(legend continued on next page)
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0.9291; p < 0.0001). HT-1080 cells were injected to the flank of
athymic nude mice. One day later, vehicle or PE (40 mg/kg)
was s.c. delivered to the nude mice with a twice-a-week
schedule for 1 week. Then, vehicle or PE (30 mg/kg) was admin-
istered to the mice through tail vein once every other day for
6 days. We observed a significant delay in tumor growth in
the PE-treated group compared to the vehicle-treated group
(Figure 6D).
The systemic toxicity and pharmacodynamics of these two
ferroptosis inducers, PE and (1S, 3R)-RSL3, were assessed
by injecting the compounds through the tail vein at 60 and
10 mg/kg, respectively. At these doses, we observed upregula-
tion of Ptgs2 in mouse liver (Figure 6E). In contrast, tail vein injec-
tion of the chemotherapeutic agent doxorubicin did not show
any induction of Ptgs2 in the same tissue, confirming the speci-
ficity of Ptgs2 as a pharmacodynamic marker (Figure 6E). As a
control, we detected robust upregulation of the p21 gene, a
biomarker for p53 activation induced by doxorubicin-mediated
DNA damage (Figure 6E). Regardless of ferroptosis activation
in the liver, we observed no overt toxicity in either animal study,
as assessed by the lack of acute lethality, and the lack of signif-
icant body weight reductions. Independently, NCI’s DTP (devel-
opmental therapeutics program) evaluated in vivo the toxicity of
intraperitoneal injection of (1S, 3R)-RSL3 and observed no
toxicity up to 400mg/kg dose, which suggested that these doses
of (1S, 3R)-RSL3 were well tolerated (Figure S6).
Diffuse Large B Cell Lymphomas and Renal Cell
Carcinomas Are Sensitive to Ferroptosis
We investigated whether the mutation status of RAS genes in
cancer cells is a predictor of sensitivity to erastin-induced ferrop-
totic cell death, by testing erastin in 117 cancer cell lines from
different tissues such as hematopoietic and lymphoid tissue,
large intestine, lung, ovary, and skin (Table S5). The cancer cell
line panel contained 38 cancer cell lines with oncogenic-RAS
mutations, which allowed us to examine the correlation between
RAS mutation status and erastin potency.
Although erastin displayed synthetic lethality in the engineered
cells, it did not show selective lethality in RAS-mutated cancer
cell lines over RAS wild-type counterparts (Figures S7A and
S7B) in this large and diverse panel of cell lines. Although RAS
mutations sensitize to ferroptosis in an individual genetic
context, there are other more dominant determinants of sensi-
tivity when analyzing sensitivity across diverse contexts. Anal-
ysis of the 117-cell line erastin sensitivity data revealed that
diffuse large B cell lymphomas (DLBCLs) were particularly sensi-
tive (Figure 7A). When we divided the 117 cell lines into sensitive
and resistant groups based on AUC values (sensitive if AUC <
3.5, resistant if AUC > 5.5), DLBCLs were enriched in the sensi-
tive group (Figure 7A, p = 0.01 by chi-square test; p = 0.025 by(D) PE showed efficacy in preventing HT-1080 tumor formation in a mouse xenog
liver microsome assay demonstrating improved metabolic stability of PE over era
right view shows images representative of tumors in live mice from each treatm
through tail vein injection once every other day for 6 days.
(E) Pharmacodynamics of PE and (1S, 3R)-RSL3 in the mouse liver tissue.
Bar graphs in (B), (C), and (E) represent mean ±SD (n = 3). In (C) and (D), the lines in
See also Figure S6 and Table S4.
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drug-screening analysis, it was observed that suspension cell
lines were generally more sensitive to growth inhibitory effects
of small molecules (Basu et al., 2013). In order to examine
whether the observed sensitivity enrichment in our analysis
was due to the general sensitivity of suspension cell lines, we
tested erastin in seven DLBCL cell lines, five acute myeloid leu-
kemia (AML) cell lines, and five multiple myeloma (MM) cell lines.
The DLBCLs displayed increased sensitivity among these sus-
pension cell lines, which suggested that DLBCLs are particularly
sensitive to ferroptotic cell death (Figure 7B; see Figure S7C for
individual concentration-dependent curve).
We further analyzed the sensitivity of DLBCLs and other
hematopoietic cell lines against 203 diverse lethal compounds
to see if DLBCLs are generally sensitive to lethal compounds
(Figure 7C). DLBCL cell lines in fact displayed a slight resistance
on average to all compounds tested compared to other hemato-
poietic cell lines (p < 3 3 104, Kolmogorov-Smirnov test). This
indicates that the enhanced sensitivity of DLBCLs to erastin-
induced ferroptosis is not due to a general sensitivity to all
compounds.
We confirmed that erastin and RSL3 generated lipid peroxides
in two DLBCL cell lines: SU-DHL-8 and WSU-DLCL-2 (Fig-
ure 7D). Moreover, erastin-induced cell death was rescued by
a lipophilic antioxidant (Vit. E) in these cell lines, indicating that
cells were dying through the lipid ROS characteristic of ferropto-
sis (Figure 7E).
The potency of erastin was also determined in a 60-cancer cell
line panel (NCI60) (Shoemaker, 2006) from eight diverse tissues,
which revealed increased sensitivity of renal cell carcinomas
(RCCs), compared to the other tissues examined (Figures 7F
and S7D). We confirmed the potency of erastin in these RCC
cell lines and observed generation of lipid ROS in two represen-
tative RCC cell lines (Figures 7G and 7H). Moreover, erastin-
induced death of these cell lines was suppressed by a lipophilic
antioxidant (Vit. E) (Figure 7I). The two RCC cell lines expressed
GPX4, as determined by western blot with a GPX4-specific anti-
body (Figure 7J). Knockdown of GPX4 using siRNAs decreased
the level of GPX4 protein and was sufficient to kill these RCC cell
lines (Figure 7J). Moreover, these cells died via a characteristic
ferroptotic death upon GPX4 knockdown (Figure 7K).
DISCUSSION
Unlike other GPXs, GPX4 can catalyze the reduction of lipid per-
oxides in a complex cellular membrane environment (Brigelius-
Flohe´ and Maiorino, 2013). Systemic deletion of Gpx4 in mice
causes embryonic lethality, which was not observed when other
Gpx genes were deleted (Ran et al., 2004), suggesting a unique
role for Gpx4 in physiology. Four groups independently createdraft model. The left view shows the structure of PE. The middle view is a mouse
stin. Midazolam was used as a positive control for metabolic degradation. The
ent group. PE was delivered s.c. twice a week for 1 week and then delivered
the tumor volume plots indicate mean of nine data points. *p < 0.05; **p < 0.01.
A B
D E
HG
F
I
K
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C
Figure 7. DLBCLs and RCCs Are Sensitive to GPX4-Regulated Ferroptosis
(A) Testing erastin in 117 cancer cell lines revealed DLBCLs as a cancer subtype susceptible to ferroptosis. DLBCL cell lines are marked with lines on the left. The
table shows the name of DLBCL cell lines along with the sensitivity rank.
(B) DLBCLs were more sensitive to erastin than AML and MM cells.
(C) DLBCL cell lines are no more sensitive to lethal compounds than other hematopoietic cell lines. The total number of AUCs in the analysis was 3,883 (972 for
DLBCL and 2,911 for other hematopoietic cell lines).
(D and E) DLBCL cells died through a mechanism characteristic of ferroptosis, as determined by lipid peroxide generation and death rescue by Vit. E.
(legend continued on next page)
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conditional Gpx4 knockout mice and analyzed the cell death
mechanisms after Gpx4 inhibition (Seiler et al., 2008; Sengupta
et al., 2013; Ueta et al., 2012; Yoo et al., 2012). Lipid peroxidation
was observed in all knockout models, highlighting the impor-
tance of Gpx4 for protecting cells from detrimental effects of lipid
peroxides. Systemic deletion of Gpx4 was lethal to mice partly
due to the nervous system damage caused by neuronal loss
(Seiler et al., 2008; Yoo et al., 2012).
In models in whichGpx4 deletion caused lethality or cell loss, it
is likely that ferroptosis had occurred. Indeed, mouse embryonic
fibroblasts (MEFs) fromconditionalGpx4 knockoutmicediedwith
lipid peroxide generation uponGpx4 deletion. Supplementing Vit.
E to these MEFs in culture rescued cell death (Seiler et al., 2008).
Elevation of lipid peroxidation upon GPX4 inhibition raises the
question of the source of lipid peroxides in normal cellular phys-
iology. Cellular iron may be the most important factor in lipid
peroxide generation during ferroptosis. Indeed, iron chelators
suppress ferroptosis (Yang and Stockwell, 2008a). Some onco-
genes, including RAS and MYC, are known to alter iron meta-
bolism by increasing iron abundance in cells and promoting
transformation (Kakhlon et al., 2002; O’Donnell et al., 2006).
In summary, we have determined that Gpx4 is a central regu-
lator of ferroptosis and that ferroptosis can be induced in mouse
tumor xenografts, providing a possible therapeutic application of
ferroptosis-inducing compounds. See the Extended Discussion
for more information.
EXPERIMENTAL PROCEDURES
Metabolite Profiling
Two million HT-1080 cells were seeded in 10 cm culture dishes. The next day,
cells were treated with 5 mg/ml erastin and incubated for 5 hr before metabolite
extraction. A total of 4 ml of cold 80% methanol was added to the cell mono-
layer to extract polar metabolites using a cell scraper. The cell lysate/methanol
mixture was transferred to a 15 ml tube and centrifuged at 2,0003 g at 4C for
10 min to pellet debris and proteins. The supernatant was transferred to a new
tube and stored at 80C for LC-MS/MS analysis. For lipid extract prepara-
tion, 3 ml of cold 100% isopropanol was added to the cell monolayer to scrape
cells. The resulting cell lysate/isopropanol mixture was transferred to a new
15 ml tube and centrifuged at 2,000 3 g at 4C for 10 min. The cleared super-
natant was transferred to a new tube and stored at 20C for LC-MS/MS
analysis.
RSL3 Target Identification
A total of 1.5 million cells were seeded into T225 flasks (Corning) 3 days before
treatment in order to be confluent on the day of treatment. Three days later, 20
flasks were washed with PBS three times to remove serum proteins from the
media and then treated with either 0.5 mM (1S, 3R)-RSL3-fluorescein probe
(‘‘active probe’’) or 0.5 mM (1R, 3R)-RSL3-fluorescein probe (‘‘inactive probe’’)
in serum-free media (DMEM) for 2 hr. For the competitor-treated samples, 20
flasks of cells were treatedwith 0.5 mM (1S, 3R)-RSL3 (‘‘competitor’’) for 20min(F) Sensitivity profile of 53 cancer cell lines in the ‘‘NCI60’’ cell panel against eras
(G) The eight RCC cell lines were retested with erastin to confirm their sensitivity
(H) Erastin and RSL3 generated lipid ROS in the two RCC cell lines.
(I) Cell death was rescued by a lipophilic antioxidant, Vit. E.
(J) GPX4 depletion by siGPX4 induced cell death in RCC cell lines. The western
knockdown of GPX4 by siRNAs. Scale bars, 30 mm.
(K) Ferroptosis inhibitors suppressed cell death induced by GPX4 knockdown but
cells via a nonferroptotic pathway.
Data points in (E), (G), and (I)–(K) represent mean ± SD (n = 3). **p < 0.01; ***p <
330 Cell 156, 317–331, January 16, 2014 ª2014 Elsevier Inc.prior to treatment with 0.5 mM active probe for 2 hr. (The active and inactive
probe-treated cells were treated with the equivalent amount of vehicle for
the same time period of the competitor pretreatment.)
After treatment, the cells were washed once with PBS, trypsinized, and
pelleted at 1,000 rpm. Following trypsinization, all the following steps were
performed at 4C. The pelleted cells were again washed in PBS twice to re-
move serum proteins added during the trypsinization. Cells were resuspended
in nondenaturing lysis buffer for 20 min (50 mM HEPES, 40 mM NaCl, 2 mM
EDTA, 0.5% Triton X-100, 1.5 mMNa3VO4, 50 mM NaF, 10 mMNa-pyrophos-
phate, 10 mM Na b-glycerophosphate, and Roche protease inhibitor tablet).
The resulting lysate was centrifuged at 12,000 3 g for 15 min to pellet out
insoluble materials, and the supernatant was removed. Protein concentration
was determined using the Bradford assay (Bio-Rad). Subsequent pull-down
and proteomics procedures are described in the Extended Experimental
Procedures.
In Vivo Xenograft Mouse Study
Athymic nude mice (8 weeks; Charles River Laboratories) were injected with
four million HT-1080 cells s.c. The next day, 400 ml of vehicle (0.625%
DMSO/99.375% HBSS [pH 2]) or 40 mg/kg PE was delivered to the s.c. site
where cancer cells were injected. Two days later, the s.c. injection was
repeated. Three days later, 300 ml of vehicle or 30 mg/kg PE was administered
to the mice through tail vein. Tail vein injection was repeated three more times,
once every other day before the final tumor size was measured in both groups.
The animal protocols containing all the procedures were approved by
Columbia University’s IACUC.
Statistical Analysis
All statistical analyses were performed by using Prism 6 (GraphPad Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Discussion, Extended Experi-
mental Procedures, seven figures, one data file, and five tables and can be
found with this article online at http://dx.doi.org/10.1016/j.cell.2013.12.010.
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